{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:18:22Z","timestamp":1793884702154,"version":"4.7.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"The Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["JP23fk0210131"],"award-info":[{"award-number":["JP23fk0210131"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009619","name":"The Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["JP23fk0210110"],"award-info":[{"award-number":["JP23fk0210110"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Japan Agency for Medical Research and Developpment","award":["JP23ama221410"],"award-info":[{"award-number":["JP23ama221410"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pancreatitis is known to be an important risk factor for pancreatic ductal adenocarcinoma (PDAC). However, the exact molecular mechanisms of how inflammation promotes PDAC are still not fully understood. Regnase-1, an endoribonuclease, regulates immune responses by degrading mRNAs of inflammation-related genes. Herein, we investigated the role of Regnase-1 in PDAC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Clinical significance of intratumor Regnase-1 expression was evaluated by immunohistochemistry in 39 surgically-resected PDAC patients. The functional role of Regnase-1 was investigated by pancreas-specific Regnase-1 knockout mice and Kras-mutant Regnase-1 knockout mice. The mechanistic studies with gene silencing, RNA immunoprecipitation sequencing (RIP-seq) and immune cell reconstitution were performed in human\/mouse PDAC cell lines and a syngeneic orthotopic tumor transplantation model of KrasG12D-mutant and Trp53-deficient PDAC cells.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Regnase-1 expression was negatively correlated with the clinical outcomes and an independent predictor of poor relapse-free and overall survival in PDAC patients. Pancreas-specific Regnase-1 deletion in mice promoteed pancreatic cancer with PMN-MDSC infiltration and shortened their survival. A syngeneic orthotopic PDAC model exhibited that Regnase-1 downregulation accelerated tumor progression via recruitment of intratumor CD11b<jats:sup>+<\/jats:sup> MDSCs. Mechanistically, Regnase-1 directly negatively regulated a variety of chemokines\/cytokines important for MDSC recruitment and activation, including CXCL1, CXCL2, CSF2, and TGF\u03b2, in pancreatic cancer cells. We subsequently showed that IL-1\u03b2-mediated Regnase-1 downregulation recruited MDSCs to tumor sites and promoted pancreatic cancer progression via mitigation of cytotoxic T lympohocytes-mediated antitumor immunity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>IL-1b-mediated Regnase-1 downregulation induces MDSCs and promotes pancreatic cancer through the evasion of anticancer immunity.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13046-023-02831-w","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T07:42:14Z","timestamp":1696837334000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Regnase-1 downregulation promotes pancreatic cancer through myeloid-derived suppressor cell-mediated evasion of anticancer immunity"],"prefix":"10.1186","volume":"42","author":[{"given":"Junya","family":"Okabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Shigeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Matsumae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Daiku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teppei","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Shigekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Higashiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Hikita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohide","family":"Tatsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shizuo","family":"Akira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Takehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,9]]},"reference":[{"issue":"11","key":"2831_CR1","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913\u201321.","journal-title":"Cancer Res"},{"issue":"1","key":"2831_CR2","doi-asserted-by":"publisher","first-page":"16425","DOI":"10.1038\/s41598-020-73525-y","volume":"10","author":"A Bengtsson","year":"2020","unstructured":"Bengtsson A, Andersson R, Ansari D. The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data. Sci Rep. 2020;10(1):16425.","journal-title":"Sci Rep"},{"issue":"4","key":"2831_CR3","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1053\/j.gastro.2013.12.033","volume":"146","author":"UC Bang","year":"2014","unstructured":"Bang UC, Benfield T, Hyldstrup L, Bendtsen F, Beck Jensen JE. Mortality, cancer, and comorbidities associated with chronic pancreatitis: a Danish nationwide matched-cohort study. Gastroenterology. 2014;146(4):989\u201394.","journal-title":"Gastroenterology"},{"key":"2831_CR4","doi-asserted-by":"crossref","unstructured":"Bansod S, Dodhiawala PB, Lim KH. Oncogenic KRAS-Induced Feedback Inflammatory Signaling in Pancreatic Cancer: An Overview and New Therapeutic Opportunities. Cancers (Basel). 2021;13(21).","DOI":"10.3390\/cancers13215481"},{"issue":"3","key":"2831_CR5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41577-020-0391-5","volume":"21","author":"SR Paludan","year":"2021","unstructured":"Paludan SR, Pradeu T, Masters SL, Mogensen TH. Constitutive immune mechanisms: mediators of host defence and immune regulation. Nat Rev Immunol. 2021;21(3):137\u201350.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"2831_CR6","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/ni.3375","volume":"17","author":"A Rivera","year":"2016","unstructured":"Rivera A, Siracusa MC, Yap GS, Gause WC. Innate cell communication kick-starts pathogen-specific immunity. Nat Immunol. 2016;17(4):356\u201363.","journal-title":"Nat Immunol"},{"key":"2831_CR7","doi-asserted-by":"crossref","unstructured":"Gupta S, Kaplan MJ. Bite of the wolf: innate immune responses propagate autoimmunity in lupus. J Clin Invest. 2021;131(3).","DOI":"10.1172\/JCI144918"},{"key":"2831_CR8","doi-asserted-by":"crossref","unstructured":"Kany S, Vollrath JT, Relja B. Cytokines in Inflammatory Disease. Int J Mol Sci. 2019;20(23).","DOI":"10.3390\/ijms20236008"},{"issue":"1","key":"2831_CR9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/imr.13023","volume":"304","author":"T Mino","year":"2021","unstructured":"Mino T, Takeuchi O. Regnase-1-related endoribonucleases in health and immunological diseases. Immunol Rev. 2021;304(1):97\u2013110.","journal-title":"Immunol Rev"},{"issue":"12","key":"2831_CR10","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1093\/intimm\/dxab048","volume":"33","author":"T Uehata","year":"2021","unstructured":"Uehata T, Takeuchi O. Post-transcriptional regulation of immunological responses by Regnase-1-related RNases. Int Immunol. 2021;33(12):859\u201365.","journal-title":"Int Immunol"},{"key":"2831_CR11","doi-asserted-by":"crossref","unstructured":"Takeuchi O. Endonuclease Regnase-1\/Monocyte chemotactic protein-1-induced protein-1 (MCPIP1) in controlling immune responses and beyond. Wiley Interdiscip Rev RNA. 2018;9(1).","DOI":"10.1002\/wrna.1449"},{"issue":"3","key":"2831_CR12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10456-017-9540-2","volume":"20","author":"J Ligeza","year":"2017","unstructured":"Ligeza J, Marona P, Gach N, Lipert B, Miekus K, Wilk W, et al. MCPIP1 contributes to clear cell renal cell carcinomas development. Angiogenesis. 2017;20(3):325\u201340.","journal-title":"Angiogenesis"},{"issue":"3","key":"2831_CR13","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/jcb.25354","volume":"117","author":"E Boratyn","year":"2016","unstructured":"Boratyn E, Nowak I, Horwacik I, Durbas M, Mistarz A, Kukla M, et al. Monocyte Chemoattractant Protein-Induced Protein 1 Overexpression Modulates Transcriptome, Including MicroRNA. Human Neuroblastoma Cells J Cell Biochem. 2016;117(3):694\u2013707.","journal-title":"Human Neuroblastoma Cells J Cell Biochem"},{"issue":"6","key":"2831_CR14","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1158\/0008-5472.CAN-15-1115","volume":"76","author":"W Lu","year":"2016","unstructured":"Lu W, Ning H, Gu L, Peng H, Wang Q, Hou R, et al. MCPIP1 Selectively Destabilizes Transcripts Associated with an Antiapoptotic Gene Expression Program in Breast Cancer Cells That Can Elicit Complete Tumor Regression. Cancer Res. 2016;76(6):1429\u201340.","journal-title":"Cancer Res"},{"issue":"1","key":"2831_CR15","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1186\/s13046-019-1430-6","volume":"38","author":"K Miekus","year":"2019","unstructured":"Miekus K, Kotlinowski J, Lichawska-Cieslar A, Rys J, Jura J. Activity of MCPIP1 RNase in tumor associated processes. J Exp Clin Cancer Res. 2019;38(1):421.","journal-title":"J Exp Clin Cancer Res"},{"issue":"12","key":"2831_CR16","doi-asserted-by":"publisher","first-page":"4311","DOI":"10.1111\/cas.15569","volume":"113","author":"K Sato","year":"2022","unstructured":"Sato K, Hikita H, Shigekawa M, Kato S, Sasaki Y, Shinkai K, et al. Pentraxin 3 is an adipose tissue-related serum marker for pancreatic cancer cachexia predicting subsequent muscle mass and visceral fat loss. Cancer Sci. 2022;113(12):4311\u201326.","journal-title":"Cancer Sci"},{"issue":"5","key":"2831_CR17","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.cell.2015.04.029","volume":"161","author":"T Mino","year":"2015","unstructured":"Mino T, Murakawa Y, Fukao A, Vandenbon A, Wessels HH, Ori D, et al. Regnase-1 and Roquin Regulate a Common Element in Inflammatory mRNAs by Spatiotemporally Distinct Mechanisms. Cell. 2015;161(5):1058\u201373.","journal-title":"Cell"},{"issue":"12","key":"2831_CR18","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/ni.2137","volume":"12","author":"H Iwasaki","year":"2011","unstructured":"Iwasaki H, Takeuchi O, Teraguchi S, Matsushita K, Uehata T, Kuniyoshi K, et al. The IkappaB kinase complex regulates the stability of cytokine-encoding mRNA induced by TLR-IL-1R by controlling degradation of regnase-1. Nat Immunol. 2011;12(12):1167\u201375.","journal-title":"Nat Immunol"},{"issue":"6","key":"2831_CR19","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1084\/jem.20181078","volume":"216","author":"H Tanaka","year":"2019","unstructured":"Tanaka H, Arima Y, Kamimura D, Tanaka Y, Takahashi N, Uehata T, et al. Phosphorylation-dependent Regnase-1 release from endoplasmic reticulum is critical in IL-17 response. J Exp Med. 2019;216(6):1431\u201349.","journal-title":"J Exp Med"},{"key":"2831_CR20","doi-asserted-by":"publisher","first-page":"104254","DOI":"10.1016\/j.cellimm.2020.104254","volume":"359","author":"R Weber","year":"2021","unstructured":"Weber R, Groth C, Lasser S, Arkhypov I, Petrova V, Altevogt P, et al. IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy. Cell Immunol. 2021;359:104254.","journal-title":"Cell Immunol"},{"issue":"16","key":"2831_CR21","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1042\/CS20191211","volume":"134","author":"G van Duijneveldt","year":"2020","unstructured":"van Duijneveldt G, Griffin MDW, Putoczki TL. Emerging roles for the IL-6 family of cytokines in pancreatic cancer. Clin Sci (Lond). 2020;134(16):2091\u2013115.","journal-title":"Clin Sci (Lond)"},{"issue":"6","key":"2831_CR22","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.ccr.2011.05.011","volume":"19","author":"C Guerra","year":"2011","unstructured":"Guerra C, Collado M, Navas C, Schuhmacher AJ, Hern\u00e1ndez-Porras I, Ca\u00f1amero M, et al. Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell. 2011;19(6):728\u201339.","journal-title":"Cancer Cell"},{"issue":"40","key":"2831_CR23","doi-asserted-by":"publisher","first-page":"65982","DOI":"10.18632\/oncotarget.11786","volume":"7","author":"NS Nagathihalli","year":"2016","unstructured":"Nagathihalli NS, Castellanos JA, VanSaun MN, Dai X, Ambrose M, Guo Q, et al. Pancreatic stellate cell secreted IL-6 stimulates STAT3 dependent invasiveness of pancreatic intraepithelial neoplasia and cancer cells. Oncotarget. 2016;7(40):65982\u201392.","journal-title":"Oncotarget"},{"issue":"5","key":"2831_CR24","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1158\/0008-5472.CAN-07-5704","volume":"68","author":"JH Egberts","year":"2008","unstructured":"Egberts JH, Cloosters V, Noack A, Schniewind B, Thon L, Klose S, et al. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res. 2008;68(5):1443\u201350.","journal-title":"Cancer Res"},{"issue":"1","key":"2831_CR25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ccr.2011.12.006","volume":"21","author":"J Ling","year":"2012","unstructured":"Ling J, Kang Y, Zhao R, Xia Q, Lee DF, Chang Z, et al. KrasG12D-induced IKK2\/beta\/NF-kappaB activation by IL-1alpha and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21(1):105\u201320.","journal-title":"Cancer Cell"},{"issue":"5","key":"2831_CR26","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1158\/0008-5472.CAN-19-2080","volume":"80","author":"S Das","year":"2020","unstructured":"Das S, Shapiro B, Vucic EA, Vogt S, Bar-Sagi D. Tumor Cell-Derived IL1beta Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer. Cancer Res. 2020;80(5):1088\u2013101.","journal-title":"Cancer Res"},{"issue":"644","key":"2831_CR27","doi-asserted-by":"publisher","first-page":"eabo2137","DOI":"10.1126\/scitranslmed.abo2137","volume":"14","author":"KM Tse","year":"2022","unstructured":"Tse KM, Vandenbon A, Cui X, Mino T, Uehata T, Yasuda K, et al. Regnase-1 expression with stem loop-targeting antisense oligonucleotides alleviates inflammatory diseases. Sci Transl Med. 2022;14(644):eabo2137.","journal-title":"Sci Transl Med"},{"key":"2831_CR28","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.3389\/fimmu.2019.01099","volume":"10","author":"G Pawelec","year":"2019","unstructured":"Pawelec G, Verschoor CP, Ostrand-Rosenberg S. Myeloid-Derived Suppressor Cells: Not Only in Tumor Immunity. Front Immunol. 2019;10:1099.","journal-title":"Front Immunol"},{"key":"2831_CR29","doi-asserted-by":"publisher","first-page":"949","DOI":"10.3389\/fimmu.2019.00949","volume":"10","author":"FM Consonni","year":"2019","unstructured":"Consonni FM, Porta C, Marino A, Pandolfo C, Mola S, Bleve A, et al. Myeloid-Derived Suppressor Cells: Ductile Targets in Disease. Front Immunol. 2019;10:949.","journal-title":"Front Immunol"},{"issue":"4","key":"2831_CR30","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.semcancer.2012.01.011","volume":"22","author":"S Ostrand-Rosenberg","year":"2012","unstructured":"Ostrand-Rosenberg S, Sinha P, Beury DW, Clements VK. Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol. 2012;22(4):275\u201381.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"2831_CR31","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1136\/gutjnl-2016-312078","volume":"66","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Velez-Delgado A, Mathew E, Li D, Mendez FM, Flannagan K, et al. Myeloid cells are required for PD-1\/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer. Gut. 2017;66(1):124\u201336.","journal-title":"Gut"},{"key":"2831_CR32","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3389\/fimmu.2019.00771","volume":"10","author":"A Bruno","year":"2019","unstructured":"Bruno A, Mortara L, Baci D, Noonan DM, Albini A. Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression. Front Immunol. 2019;10:771.","journal-title":"Front Immunol"},{"issue":"2","key":"2831_CR33","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00262-014-1618-8","volume":"64","author":"J Markowitz","year":"2015","unstructured":"Markowitz J, Brooks TR, Duggan MC, Paul BK, Pan X, Wei L, et al. Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease. Cancer Immunol Immunother. 2015;64(2):149\u201359.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"2831_CR34","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41416-018-0333-1","volume":"120","author":"C Groth","year":"2019","unstructured":"Groth C, Hu X, Weber R, Fleming V, Altevogt P, Utikal J, et al. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br J Cancer. 2019;120(1):16\u201325.","journal-title":"Br J Cancer"},{"key":"2831_CR35","doi-asserted-by":"publisher","first-page":"879897","DOI":"10.1155\/2014\/879897","volume":"2014","author":"YS Khaled","year":"2014","unstructured":"Khaled YS, Ammori BJ, Elkord E. Increased levels of granulocytic myeloid-derived suppressor cells in peripheral blood and tumour tissue of pancreatic cancer patients. J Immunol Res. 2014;2014:879897.","journal-title":"J Immunol Res"},{"key":"2831_CR36","doi-asserted-by":"crossref","unstructured":"Thyagarajan A, Alshehri MSA, Miller KLR, Sherwin CM, Travers JB, Sahu RP. Myeloid-Derived Suppressor Cells and Pancreatic Cancer: Implications in Novel Therapeutic Approaches. Cancers (Basel). 2019;11(11).","DOI":"10.3390\/cancers11111627"},{"key":"2831_CR37","doi-asserted-by":"crossref","unstructured":"Sarhan D, Eisinger S, He F, Bergsland M, Pelicano C, Driescher C, et al. Targeting myeloid suppressive cells revives cytotoxic anti-tumor responses in pancreatic cancer. iScience. 2022;25(11):105317.","DOI":"10.1016\/j.isci.2022.105317"},{"issue":"4","key":"2831_CR38","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s00262-020-02701-w","volume":"70","author":"AJ Oweida","year":"2021","unstructured":"Oweida AJ, Mueller AC, Piper M, Milner D, Van Court B, Bhatia S, et al. Response to radiotherapy in pancreatic ductal adenocarcinoma is enhanced by inhibition of myeloid-derived suppressor cells using STAT3 anti-sense oligonucleotide. Cancer Immunol Immunother. 2021;70(4):989\u20131000.","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"2831_CR39","doi-asserted-by":"publisher","first-page":"e1258504","DOI":"10.1080\/2162402X.2016.1258504","volume":"6","author":"J Zhang","year":"2017","unstructured":"Zhang J, Xu X, Shi M, Chen Y, Yu D, Zhao C, et al. CD13(hi) Neutrophil-like myeloid-derived suppressor cells exert immune suppression through Arginase 1 expression in pancreatic ductal adenocarcinoma. Oncoimmunology. 2017;6(2):e1258504.","journal-title":"Oncoimmunology"},{"key":"2831_CR40","doi-asserted-by":"crossref","unstructured":"Law AMK, Valdes-Mora F, Gallego-Ortega D. Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer. Cells. 2020;9(3).","DOI":"10.3390\/cells9030561"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-023-02831-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-023-02831-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-023-02831-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T14:43:24Z","timestamp":1700318604000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-023-02831-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,9]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2831"],"URL":"https:\/\/doi.org\/10.1186\/s13046-023-02831-w","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,9]]},"assertion":[{"value":"27 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal procedures were performed in accordance with the Animal Care and Use Guidelines of Osaka University and approved by the Ethics Committee of the Osaka University Graduate School of Medicine. The use of excised human specimens was approved by the Ethics Committee of the Osaka University Graduate School of Medicine (protocol 17160), and written informed consent was obtained from all patients. The study design adhered to the tenets of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"262"}}